Cover Image
Market Research Report

Cardiac Ablation Devices - Medical Devices Pipeline Assessment, 2018

Published by GlobalData Product code 654783
Published Content info 101 Pages
Immediate Delivery Available
Price
Back to Top
Cardiac Ablation Devices - Medical Devices Pipeline Assessment, 2018
Published: June 14, 2018 Content info: 101 Pages
Description

GlobalData's Medical Devices sector report, "Cardiac Ablation Devices - Medical Devices Pipeline Assessment, 2018" provides an overview of Cardiac Ablation Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiac Ablation Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Cardiac Ablation Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Cardiac Ablation Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Cardiac Ablation Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
Product Code: GDME0585EPD

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 6

2 Introduction 7

  • 2.1 Cardiac Ablation Devices Overview 7

3 Products under Development 8

  • 3.1 Cardiac Ablation Devices - Pipeline Products by Stage of Development 8
  • 3.2 Cardiac Ablation Devices - Pipeline Products by Territory 9
  • 3.3 Cardiac Ablation Devices - Pipeline Products by Regulatory Path 10
  • 3.4 Cardiac Ablation Devices - Pipeline Products by Estimated Approval Date 11
  • 3.5 Cardiac Ablation Devices - Ongoing Clinical Trials 12

4 Cardiac Ablation Devices - Pipeline Products under Development by Companies 13

  • 4.1 Cardiac Ablation Devices Companies - Pipeline Products by Stage of Development 13
  • 4.2 Cardiac Ablation Devices - Pipeline Products by Stage of Development 14

5 Cardiac Ablation Devices Companies and Product Overview 15

  • 5.1 AblaCor Medical Corporation Company Overview 15
    • 5.1.1 AblaCor Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.2 Adagio Medical Inc. Company Overview 17
    • 5.2.1 Adagio Medical Inc. Pipeline Products & Ongoing Clinical Trials Overview 17
  • 5.3 AFreeze GmbH Company Overview 20
    • 5.3.1 AFreeze GmbH Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.4 AngioDynamics Inc Company Overview 24
    • 5.4.1 AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.5 AtriCure Inc Company Overview 25
    • 5.5.1 AtriCure Inc Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.6 CPSI Biotech Company Overview 28
    • 5.6.1 CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.7 Enigma Medical, Inc. Company Overview 29
    • 5.7.1 Enigma Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.8 Helical Solutions, Inc. (Inactive) Company Overview 30
    • 5.8.1 Helical Solutions, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.9 Johns Hopkins University Company Overview 31
    • 5.9.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.10 Kardium Inc Company Overview 32
    • 5.10.1 Kardium Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.11 LuxCath, LLC Company Overview 35
    • 5.11.1 LuxCath, LLC Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.12 Northwestern University Company Overview 36
    • 5.12.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.13 Sheba Medical Center Company Overview 37
    • 5.13.1 Sheba Medical Center Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.14 Spectranetics Corp Company Overview 38
    • 5.14.1 Spectranetics Corp Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.15 Thermedical Inc Company Overview 39
    • 5.15.1 Thermedical Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.16 Tufts Medical Center Company Overview 44
    • 5.16.1 Tufts Medical Center Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.17 University of California Los Angeles Company Overview 45
    • 5.17.1 University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.18 University of Chicago Company Overview 46
    • 5.18.1 University of Chicago Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.19 VytronUS, Inc. Company Overview 47
    • 5.19.1 VytronUS, Inc. Pipeline Products & Ongoing Clinical Trials Overview 47

6 Cardiac Ablation Devices- Recent Developments 50

  • 6.1 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results 50
  • 6.2 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 52
  • 6.3 Apr 26, 2018: AtriCure Reports First Quarter 2018 Financial Results 53
  • 6.4 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018 53
  • 6.5 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics 55
  • 6.6 Mar 29, 2018: AngioDynamics Reports Fiscal 2018 Third Quarter Financial Results 56
  • 6.7 Mar 28, 2018: Vascular Insights Announces New Chief Financial Officer 57
  • 6.8 Mar 19, 2018: In vitro study details the increased performance and potential of CPSI's Supercritical Nitrogen cryoablation device for the epicardial based ablation of cardiac tissue 58
  • 6.9 Mar 16, 2018: Vascular Insights Announces A New Lead To The Global Commercial Team 58
  • 6.10 Mar 08, 2018: Baylis Medical wins Best Managed Companies award 59
  • 6.11 Mar 06, 2018: Stereotaxis Reports 2017 Fourth Quarter And Full Year Financial Results 60
  • 6.12 Mar 05, 2018: USPTO allows AblaCor five ablation catheter-anchoring patents for its CircumBlator AF Catheter Ablation System 61
  • 6.13 Mar 05, 2018: AblaCor Appoints Lawrence Rosenthal To Its Scientific Advisory Board 62
  • 6.14 Feb 26, 2018: AtriCure Announces Fourth Quarter and Full Year 2017 Financial Results 62
  • 6.15 Feb 20, 2018: AtriCure Names Scott Drake Board Chairman 63
  • 6.16 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 64
  • 6.17 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region 66
  • 6.18 Jan 25, 2018: Vascular Insights Announces New Chief Executive Officer 66
  • 6.19 Jan 22, 2018: Baylis Medical embraces advanced manufacturing with opening of state-of-the-art lab 67
  • 6.20 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 68
  • 6.21 Jan 08, 2018: AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2017 68
  • 6.22 Jan 08, 2018: Stereotaxis Reports Preliminary Fourth Quarter 2017 Revenue Results 68
  • 6.23 Jan 04, 2018: AngioDynamics Reports Fiscal 2018 Second Quarter Financial Results 69
  • 6.24 Dec 19, 2017: Bob White Named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group; Chris Lee to Assume Leadership of Medtronic's Asia Pacific Region 70
  • 6.25 Nov 21, 2017: Medtronic Reports Second Quarter Financial Results 71
  • 6.26 Nov 09, 2017: Stereotaxis Reports Third Quarter 2017 Financial Results 74
  • 6.27 Nov 08, 2017: Medtronic Announces Preliminary Second Quarter Revenue 76
  • 6.28 Nov 02, 2017: Medtronic Releases Fiscal Year 2017 Integrated Performance Report 77
  • 6.29 Nov 01, 2017: AtriCure Reports Third Quarter 2017 Financial Results 77
  • 6.30 Oct 26, 2017: Boston Scientific Announces Results For Third Quarter 2017 78
  • 6.31 Oct 25, 2017: Baylis Medical's Kris Shah appointed to AdvaMed Accel Board of Directors 80
  • 6.32 Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria 80
  • 6.33 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary 81
  • 6.34 Sep 28, 2017: AngioDynamics Reports Fiscal 2018 First Quarter Results 82
  • 6.35 Aug 23, 2017: Baylis Medical strengthens global expansion plans with senior hire 83
  • 6.36 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 84
  • 6.37 Aug 10, 2017: Stereotaxis Reports Second Quarter 2017 Financial Results 86
  • 6.38 Aug 03, 2017: Spectranetics Reports Second Quarter 2017 Revenue of $74.7 million 87
  • 6.39 Aug 02, 2017: SAMHSA announces $6 million in grants to support the International President's Emergency Plan for AIDS Relief Addiction Technology Transfer Centers 88
  • 6.40 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 88
  • 6.41 Jul 27, 2017: AtriCure Reports Second Quarter 2017 Financial Results 90
  • 6.42 Jul 18, 2017: AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results 91
  • 6.43 Jul 18, 2017: AtriCure Announces Hiring of Chief Technology Officer 93
  • 6.44 Jul 11, 2017: A study confirms epicardial ablation as an effective treatment of Brugada Syndrome in patients at risk of ventricular fibrillation 93
  • 6.45 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 94
  • 6.46 Jun 14, 2017: Spectranetics Announces Election of New Chairperson of the Board of Directors 96

7 Appendix 98

  • 7.1 Methodology 98
  • 7.2 About GlobalData 101
  • 7.3 Contact Us 101
  • 7.4 Disclaimer 101

List of Tables

  • Table 1: Cardiac Ablation Devices - Pipeline Products by Stage of Development 8
  • Table 2: Cardiac Ablation Devices - Pipeline Products by Territory 9
  • Table 3: Cardiac Ablation Devices - Pipeline Products by Regulatory Path 10
  • Table 4: Cardiac Ablation Devices - Pipeline Products by Estimated Approval Date 11
  • Table 5: Cardiac Ablation Devices - Ongoing Clinical Trials 12
  • Table 6: Cardiac Ablation Devices Companies - Pipeline Products by Stage of Development 13
  • Table 7: Cardiac Ablation Devices - Pipeline Products by Stage of Development 14
  • Table 8: AblaCor Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 15
  • Table 9: AutoBlator - Product Status 15
  • Table 10: AutoBlator - Product Description 15
  • Table 11: CircumBlator AF Catheter Ablation System - Product Status 16
  • Table 12: CircumBlator AF Catheter Ablation System - Product Description 16
  • Table 13: Adagio Medical Inc. Pipeline Products & Ongoing Clinical Trials Overview 17
  • Table 14: PolarStar System - Product Status 17
  • Table 15: PolarStar System - Product Description 17
  • Table 16: Adagio Medical Inc. - Ongoing Clinical Trials Overview 18
  • Table 17: PolarStar System - A Prospective, Multicenter Investigation of the Adagio Cryoablation System in Patients with Atrial Fibrillation 19
  • Table 18: PolarStar System - A Prospective, Multicenter, Investigation of the Adagio PolarStar System in Subjects with Atrial Flutter 19
  • Table 19: AFreeze GmbH Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 20: CoolLoop - Product Status 20
  • Table 21: CoolLoop - Product Description 20
  • Table 22: Tip-Catheter - Product Status 21
  • Table 23: Tip-Catheter - Product Description 21
  • Table 24: AFreeze GmbH - Ongoing Clinical Trials Overview 22
  • Table 25: CoolLoop - CoolLoop Paroxysmal Atrial Fibrillation 23
  • Table 26: AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 24
  • Table 27: Non-Thermal Vein Ablation Device - Product Status 24
  • Table 28: Non-Thermal Vein Ablation Device - Product Description 24
  • Table 29: AtriCure Inc Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 30: AtriCure Bipolar System - Product Status 25
  • Table 31: AtriCure Bipolar System - Product Description 25
  • Table 32: AtriCure Inc - Ongoing Clinical Trials Overview 26
  • Table 33: AtriCure Bipolar System - Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation 27
  • Table 34: CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 35: ICEolate Catheter - Product Status 28
  • Table 36: ICEolate Catheter - Product Description 28
  • Table 37: Enigma Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 38: Enigma Device - Product Status 29
  • Table 39: Enigma Device - Product Description 29
  • Table 40: Helical Solutions, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 41: Catheter-Based Ablation Device - Product Status 30
  • Table 42: Catheter-Based Ablation Device - Product Description 30
  • Table 43: Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 44: Catheter Guiding Computational Modeling Tool - Product Status 31
  • Table 45: Catheter Guiding Computational Modeling Tool - Product Description 31
  • Table 46: Kardium Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 47: Globe Mapping And Ablation System - Product Status 32
  • Table 48: Globe Mapping And Ablation System - Product Description 32
  • Table 49: Kardium Inc - Ongoing Clinical Trials Overview 33
  • Table 50: Globe Mapping And Ablation System - A Prospective, Non-randomized Clinical Study to Assess Safety and Performance of a Device for Global Mapping and Ablation of the Left Atrium for the Treatment of Atrial Fibrillation 34
  • Table 51: LuxCath, LLC Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 52: OmniView Light-Guided Ablation Catheter - Product Status 35
  • Table 53: OmniView Light-Guided Ablation Catheter - Product Description 35
  • Table 54: Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 55: Cardiac Tissue Ablation Device - Product Status 36
  • Table 56: Cardiac Tissue Ablation Device - Product Description 36
  • Table 57: Sheba Medical Center Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 58: Transcatheter Septal Myectomy Device - Product Status 37
  • Table 59: Transcatheter Septal Myectomy Device - Product Description 37
  • Table 60: Spectranetics Corp Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 61: Nexcimer - Product Status 38
  • Table 62: Nexcimer - Product Description 38
  • Table 63: Thermedical Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 64: Durablate Ablation Catheter - Product Status 39
  • Table 65: Durablate Ablation Catheter - Product Description 39
  • Table 66: SERF Ablation System - Ventricular Tachycardia - Product Status 40
  • Table 67: SERF Ablation System - Ventricular Tachycardia - Product Description 40
  • Table 68: Thermedical Inc - Ongoing Clinical Trials Overview 41
  • Table 69: SERF Ablation System - Ventricular Tachycardia - Saline-enhanced Radiofrequency (SERF) Catheter Ablation for the Treatment of Ventricular Tachycardia 42
  • Table 70: Durablate Ablation Catheter - Saline-enhanced Radiofrequency (SERF) Catheter Ablation for the Treatment of Ventricular Tachycardia 43
  • Table 71: Tufts Medical Center Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 72: Tissue Ablation Device - Product Status 44
  • Table 73: Tissue Ablation Device - Product Description 44
  • Table 74: University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 75: Cryogenic Anchor - Product Status 45
  • Table 76: Cryogenic Anchor - Product Description 45
  • Table 77: University of Chicago Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 78: DVT Histotripsy System - Product Status 46
  • Table 79: DVT Histotripsy System - Product Description 46
  • Table 80: VytronUS, Inc. Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 81: Low-Intensity Collimated Ultrasound (LICU) Cardiac Mapping and Ablation System - Product Status 47
  • Table 82: Low-Intensity Collimated Ultrasound (LICU) Cardiac Mapping and Ablation System - Product Description 47
  • Table 83: VytronUS, Inc. - Ongoing Clinical Trials Overview 48
  • Table 84: Low-Intensity Collimated Ultrasound (LICU) Cardiac Mapping and Ablation System - Clinical Investigation of the VytronUS Ablation System for Treatment of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillation 49
  • Table 85: Glossary 100

List of Figures

  • Figure 1: Cardiac Ablation Devices - Pipeline Products by Stage of Development 8
  • Figure 2: Cardiac Ablation Devices - Pipeline Products by Territory 9
  • Figure 3: Cardiac Ablation Devices - Pipeline Products by Regulatory Path 10
  • Figure 4: Cardiac Ablation Devices - Pipeline Products by Estimated Approval Date 11
  • Figure 5: Cardiac Ablation Devices - Ongoing Clinical Trials 12
Back to Top